Vertex Pharmaceuticals

Vertex Pharmaceuticals (Boston, MA). 2024 revenue ~$11B. Cystic fibrosis monopoly: Trikafta, Kaftrio. CASGEVY (exa-cel, CRISPR gene therapy for SCD). Suzetrigine (VX-548, non-opioid painkiller) — breakthrough 2025.